Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Study looks at nicotine gum, smoking cessation

This article was originally published in The Tan Sheet

Executive Summary

Smokers who began nicotine gum treatment four weeks prior to a target date to quit smoking were no less likely to stop smoking or experience withdrawal symptoms than subjects who started using the gum on their quit date, according to a Swiss study. Researchers led by Jean-Francois Etter, of the University of Geneva's Institute of Social and Preventive Medicine, hypothesized that pre-cessation treatment with gum would be more effective than post-cessation treatment because they "thought that obtaining nicotine from gum instead of cigarettes would weaken cigarette reinforcement." The researchers write in a report published June 8 in the Archives of Internal Medicine that the 314 daily smokers studied might have had better success with additional face-to-face counseling or with a nicotine patch, which maintains a steady level of the drug in the bloodstream. Although the study results dispute the status of nicotine gum as a "cut down to quit" product in many countries, the researchers say there remains "a need to explore strategies to increase the reach and efficacy" of nicotine replacement therapies

You may also be interested in...



Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Could Eledon’s Anti-CD40L Change Transplant Medicine?

Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation. 

Turning That Frown Upside Down: Treating Depression With Facial Botox Injections

In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103024

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel